In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease

NJ Ray, S Bradburn, C Murgatroyd, U Toseeb, P Mir… - Brain, 2018 - academic.oup.com
Abstract See Gratwicke and Foltynie (doi: 10.1093/brain/awx333) for a scientific commentary
on this article. Cognitive impairments are a prevalent and disabling non-motor complication …

In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease

NJ Ray, S Bradburn, C Murgatroyd… - Brain: a journal of …, 2018 - eprints.whiterose.ac.uk
Cognitive impairments are a prevalent and disabling non-motor complication of Parkinson's
disease, but with variable expression and progression. The onset of serious cognitive …

[PDF][PDF] In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease

NJ Ray, S Bradburn, C Murgatroyd, U Toseeb, P Mir… - BRAIN, 2018 - core.ac.uk
Cognitive impairment is a major non-motor complication of Parkinson's disease and is
associated with significant disability and reduced quality of life (Lawson et al., 2016). The …

[HTML][HTML] In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease

NJ Ray, S Bradburn, C Murgatroyd, U Toseeb, P Mir… - Brain, 2018 - ncbi.nlm.nih.gov
In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson’s
disease - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …

[PDF][PDF] In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease

NJ Ray, S Bradburn, C Murgatroyd, U Toseeb, P Mir… - 2017 - researchgate.net
Cognitive impairment is a major non-motor complication of Parkinson's disease and is
associated with significant disability and reduced quality of life (Lawson et al., 2016). The …

In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease

NJ Ray, S Bradburn, C Murgatroyd, U Toseeb, P Mir… - Brain, 2018 - e-space.mmu.ac.uk
Cognitive impairments are a prevalent and disabling non-motor complication of Parkinson's
disease, but with variable expression and progression. The onset of serious cognitive …

In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease

NJ Ray, S Bradburn, C Murgatroyd… - Brain: a journal of …, 2018 - pubmed.ncbi.nlm.nih.gov
See Gratwicke and Foltynie (doi: 10.1093/brain/awx333) for a scientific commentary on this
article. Cognitive impairments are a prevalent and disabling non-motor complication of …

In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease.

NJ Ray, S Bradburn, C Murgatroyd… - Brain: a Journal of …, 2018 - europepmc.org
See Gratwicke and Foltynie (doi: 10.1093/brain/awx333) for a scientific commentary on this
article. Cognitive impairments are a prevalent and disabling non-motor complication of …

[引用][C] In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease

NJ Ray, S Bradburn, C Murgatroyd, U Toseeb, P Mir… - Brain, 2017 - cir.nii.ac.jp
In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson’s
disease | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …

In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease

NJ Ray, S Bradburn, C Murgatroyd… - Brain: a journal of …, 2018 - pure.york.ac.uk
Cognitive impairments are a prevalent and disabling non-motor complication of Parkinson's
disease, but with variable expression and progression. The onset of serious cognitive …